---
title: "According to \"The Big Bank,\" Bank of America Securities has lowered the target price for Zai Lab to 19.92 yuan, citing pressure on core product sales"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265062379.md"
description: "Bank of America Securities lowered the target price for Zai Lab to RMB 19.92 due to pressure on its core product sales. The report pointed out that the company's total revenue in the third quarter increased by 13% year-on-year to USD 116 million, and the net loss narrowed by 14% to USD 36 million. The full-year revenue guidance was lowered to USD 460 million, and revenue forecasts for 2025 to 2027 were reduced by 17%, 23%, and 20%, respectively. The \"Neutral\" rating was reaffirmed, with R&D pipeline progress meeting expectations"
datetime: "2025-11-10T03:12:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265062379.md)
  - [en](https://longbridge.com/en/news/265062379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265062379.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265062379.md) | [繁體中文](https://longbridge.com/zh-HK/news/265062379.md)


# According to "The Big Bank," Bank of America Securities has lowered the target price for Zai Lab to 19.92 yuan, citing pressure on core product sales

Bank of America Securities research report indicates that Zai Lab (09688.HK) total revenue in the third quarter increased by 13% year-on-year to USD 116 million, with product revenue also rising by 13% year-on-year to USD 115 million. Among these, revenue from VYVGART and VYVGART Hytrulo, ZEJULA, and NUZYRA increased by 2%, decreased by 12%, and increased by 54% year-on-year, respectively. The net loss narrowed by 14% year-on-year to USD 36 million. The company has lowered its full-year revenue guidance from the original range of USD 560 million to USD 590 million down to USD 460 million.

The firm has reduced its revenue forecasts for 2025 to 2027 by 17%, 23%, and 20%, respectively, and has lowered its gross margin forecasts for 2025 and 2026 by 0.3 and 0.2 percentage points, but raised the gross margin forecast for 2027 by 0.4 percentage points due to expected product portfolio adjustments. The target price for Zai Lab's U.S. stock (ZLAB.US) has been lowered from USD 31.6 to USD 25.7, and the target price for its Hong Kong stock has been reduced from HKD 24.49 to HKD 19.92, reiterating a "Neutral" rating, as the progress of the R&D pipeline meets expectations, but core products face sales pressure

### Related Stocks

- [Zai Lab Limited (ZLAB.US)](https://longbridge.com/en/quote/ZLAB.US.md)
- [ZAI LAB (09688.HK)](https://longbridge.com/en/quote/09688.HK.md)

## Related News & Research

- [Zai Lab's Q3 Loss Narrows as Revenue Jumps 14%; Shares Fall 8%](https://longbridge.com/en/news/264767884.md)
- [Guotai Haitong Remains a Buy on Zai Lab Ltd (1ZLB)](https://longbridge.com/en/news/277338249.md)
- [Deutsche Bank trims Sandvik price target to SEK 398 (404), reiterates Buy](https://longbridge.com/en/news/281309564.md)
- [GOLDMAN: `NO CLEAR CATALYST` FOR 2026 POLICY RATE CUT IN CHINA](https://longbridge.com/en/news/281350693.md)
- [Managers' transactions announcement according to article 19 MAR](https://longbridge.com/en/news/281158113.md)